Idera Pharmaceuticals, Inc.
IDRANASDAQHealthcare
$0.43
$-0.13(-23.04%)
Market Cap$0
P/E Ratio—
52W High$16.0
52W Low$0.4201
Idera Pharmaceuticals, Inc. (IDRA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IDRA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2023Report Date: Jun 29, 2023EPS Actual
-$2935.64
Revenue
—
Fiscal Period
Q2 FY2023
FY ends December
Report Date
Jun 29, 2023
After Market Close
IDRA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2023 | Jun 29, 2023 | — | -$2935.64 | — | — | — | — |
| — Q1 FY2023 | Mar 29, 2023 | — | -$3.30 | — | $-0.00B | — | — |
| — Q4 FY2022 | Nov 14, 2022 | — | $1.02 | — | $0.00B | — | — |
| — Q3 FY2022 | Aug 9, 2022 | — | -$0.10 | — | — | — | — |
| ▼ Q2 FY2022 | May 5, 2022 | -$0.11 | -$1.36 | -1136.4% | — | — | — |
| ▼ Q1 FY2022 | Mar 31, 2022 | -$0.11 | -$1.36 | -1136.4% | — | — | — |
| ▼ Q4 FY2021 | Nov 8, 2021 | -$0.12 | -$1.87 | -1458.3% | — | — | — |
| ▼ Q3 FY2021 | Aug 9, 2021 | -$0.18 | -$2.55 | -1316.7% | — | — | — |
Q2 FY2023
Jun 29, 2023
EPS Actual
-$2935.64
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 29, 2023
EPS Actual
-$3.30
EPS Est.
—
EPS Surpr.
—
Revenue
$-0.00B
Q4 FY2022
Nov 14, 2022
EPS Actual
$1.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Aug 9, 2022
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
May 5, 2022Miss
EPS Actual
-$1.36
EPS Est.
-$0.11
EPS Surpr.
-1136.4%
Revenue
—
Q1 FY2022
Mar 31, 2022Miss
EPS Actual
-$1.36
EPS Est.
-$0.11
EPS Surpr.
-1136.4%
Revenue
—
Q4 FY2021
Nov 8, 2021Miss
EPS Actual
-$1.87
EPS Est.
-$0.12
EPS Surpr.
-1458.3%
Revenue
—
Q3 FY2021
Aug 9, 2021Miss
EPS Actual
-$2.55
EPS Est.
-$0.18
EPS Surpr.
-1316.7%
Revenue
—
No analyst estimates available for IDRA.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2023 | Jun 29, 2023 | — | $0.43 | — | — |
| — Q1 FY2023 | Mar 29, 2023 | — | $0.43 | — | — |
| — Q4 FY2022 | Nov 14, 2022 | — | $0.41 | $0.40 | -3.02% |
| — Q3 FY2022 | Aug 9, 2022 | — | $0.42 | $0.45 | +7.31% |
| ▼ Q2 FY2022 | May 5, 2022 | -1136.4% | $0.44 | $0.43 | -2.32% |
| ▼ Q1 FY2022 | Mar 31, 2022 | -1136.4% | $0.52 | $0.50 | -4.45% |
| ▼ Q4 FY2021 | Nov 8, 2021 | -1458.3% | $0.85 | $0.86 | +1.60% |
| ▼ Q3 FY2021 | Aug 9, 2021 | -1316.7% | $1.06 | $1.07 | +0.94% |
Q2 FY2023—
Report Date
Jun 29, 2023
EPS Beat/Miss
—
Price Before
$0.43
Price After
—
Q1 FY2023—
Report Date
Mar 29, 2023
EPS Beat/Miss
—
Price Before
$0.43
Price After
—
Q4 FY2022-3.02%
Report Date
Nov 14, 2022
EPS Beat/Miss
—
Price Before
$0.41
Price After
$0.40
Q3 FY2022+7.31%
Report Date
Aug 9, 2022
EPS Beat/Miss
—
Price Before
$0.42
Price After
$0.45
Q2 FY2022-2.32%
Report Date
May 5, 2022
EPS Beat/Miss
-1136.4%
Price Before
$0.44
Price After
$0.43
Q1 FY2022-4.45%
Report Date
Mar 31, 2022
EPS Beat/Miss
-1136.4%
Price Before
$0.52
Price After
$0.50
Q4 FY2021+1.60%
Report Date
Nov 8, 2021
EPS Beat/Miss
-1458.3%
Price Before
$0.85
Price After
$0.86
Q3 FY2021+0.94%
Report Date
Aug 9, 2021
EPS Beat/Miss
-1316.7%
Price Before
$1.06
Price After
$1.07
Avg Miss Reaction-1.06%
Beat Rate0 / 8 quarters
Largest Move+7.31% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IDRA ends December
Idera Pharmaceuticals, Inc. (IDRA) most recently reported earnings on June 29, 2023 for Q2 FY2023, posting EPS of $-2935.64 (in line with the analyst consensus of —). The next IDRA earnings date is expected around September 1, 2026.
Each quarter, investors track IDRA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IDRA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IDRA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IDRA earnings · 4 questionsIdera Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. IDRA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IDRA historically reports after market close (AMC).
IDRA earnings datewhen is IDRA earningsIDRA next earnings datewhen does IDRA report earningsIDRA earnings calendar
▸ Source: FMP · Idera Pharmaceuticals, Inc. SEC filings · US GAAP · Idera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026